David Altshuler, geneticist who helped transform Vertex, to retire next year

Since becoming Vertex's top scientist in 2015, Altshuler has shaped the company’s efforts to expand beyond cystic fibrosis.

US biotech needs government support to match China’s gains, Pfizer CEO says

“The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in comments on China’s rising competitiveness.

Maximizing ROI with early-stage claims data

HHS abandons mRNA vaccine research

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step backward for science.” 

Regeneron cancer bispecific rejected again; Allogene discloses trial death

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

Sarepta hired Trump-linked Michael Best Strategies to lobby

FDA Chief Says He Wants Gene Therapy Head Prasad to Return

3 BLAs in 3 Years: Ocugen Sees Potential in Eye Disease Gene Therapies